Affiliated with a Castle Connolly Top Hospital
Who is Dr. Ganjoo, Medical Oncologist in Stanford, CA?
Dr. Kristen Ganjoo, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She is board certified by the American Board of Internal Medicine. Dr. Ganjoo completed her residency at Indiana University. Dr. Ganjoo is fluent in English and Persian, and is currently seeing new patients. Dr. Ganjoo’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Ganjoo’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Ganjoo?
Dr. Kristen Ganjoo, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Ganjoo empowers patients to confidently navigate their health journey, specializing in Sarcoma-Soft Tissue, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Ganjoo is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Ganjoo go to medical school and complete their residency?
Fellowship: Indiana University / School of Medicine
Residency: Indiana University
Is Dr. Ganjoo board certified in Medical Oncologist?
Yes, Dr. Kristen Ganjoo, MD is board certified by the American Board of Internal Medicine since 2000
What languages does Dr. Ganjoo speak?
Dr. Ganjoo and their clinical team can communicate with patients in the following languages:
English
Persian
What conditions does Dr. Ganjoo treat?
As a Medical Oncologist, Dr. Ganjoo diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Ganjoo. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Soft Tissue Sarcoma
- Cancer
- Connective Tissue Disorder
- Malignant Soft Tissue Tumor
- Connective Tissue Cancer
- Soft Tissue Cancer
ICD-10 Codes:
- C499: Malignant neoplasm of connective and soft tissue, unspecified
- C493: Malignant neoplasm of connective and soft tissue of thorax
- C4921: Malignant neoplasm of connective and soft tissue of right lower limb, including hip
Also known as:
- Uterine Cancer
- Endometrial Cancer Treatment (PDQ®)
- Endometrial Cancer Treatment (PDQ)
- Malignant Uterine Tumor
- Uterine Carcinoma
- Cancer of the Uterus
- Womb cancer
- Endometrial cancer
- Uterine carcinoma
ICD-10 Codes:
- C55: Malignant neoplasm of uterus, part unspecified
- C549: Malignant neoplasm of corpus uteri, unspecified
Also known as:
- Bone Cancer
- Cancer
- Primary Bone Cancer
- Malignant Bone Tumor
- Bone Sarcoma
- Osteosarcoma
ICD-10 Codes:
- C419: Malignant neoplasm of bone and articular cartilage, unspecified
Also known as:
- Gastrointestinal Stromal Tumor
- Retroperitoneal Cancer
- Gastrointestinal stromal tumor
- Cancer
- GIST
- GI stromal tumor
- Stomach and bowel tumor
- Retroperitoneal Tumor
- Malignant Retroperitoneal Neoplasm
- Abdominal Cancer
ICD-10 Codes:
- C49A0: Gastrointestinal stromal tumor, unspecified site
- C480: Malignant neoplasm of retroperitoneum
Also known as:
- Stomach Gastrointestinal Stromal Tumor
- Small Intestine Gastrointestinal Stromal Tumor
- Gastrointestinal stromal tumor
- GIST of stomach
- Gastric GIST
- Stomach tumor
- GIST of small intestine
- Small bowel GIST
- Small intestine tumor
ICD-10 Codes:
- C49A2: Gastrointestinal stromal tumor of stomach
- C49A3: Gastrointestinal stromal tumor of small intestine
Also known as:
- Soft Tissue Tumor of Uncertain Behavior
- Connective Tissue Disorder
- Connective Tissue Neoplasm
- Soft Tissue Growth
- Uncertain Soft Tissue Mass
ICD-10 Codes:
- D481: Neoplasm of uncertain behavior of connective and other soft tissue
Also known as:
- Desmoid Tumor
- Desmoid tumor
- Aggressive Fibromatosis
- Deep Fibromatosis
- Desmoid Fibromatosis
ICD-10 Codes:
- D48119: Desmoid tumor of unspecified site
Also known as:
- Soft Tissue Cancer of Head, Face, or Neck
- Cancer
- Connective Tissue Disorder
- Head and Neck Sarcoma
- Facial Soft Tissue Cancer
- Neck Soft Tissue Tumor
- Head Soft Tissue Malignancy
ICD-10 Codes:
- C490: Malignant neoplasm of connective and soft tissue of head, face and neck
Also known as:
- Gastrointestinal Stromal Tumor
- Gastrointestinal stromal tumor
- GIST
- GI Stromal Tumor
- Large Intestine Tumor
ICD-10 Codes:
- C49A4: Gastrointestinal stromal tumor of large intestine
Also known as:
- Secondary Bone Cancer
- Bone Cancer
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
ICD-10 Codes:
- C7951: Secondary malignant neoplasm of bone
Also known as:
- Cancer Chemotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
Also known as:
- Kaposi Sarcoma
- KS
- Kaposi's Cancer', 'Kaposi's Tumor
ICD-10 Codes:
- C469: Kaposi's sarcoma, unspecified
Also known as:
- Breast Cancer
- Female Breast Cancer
- Malignant Breast Tumor
- Breast Carcinoma
ICD-10 Codes:
- C50919: Malignant neoplasm of unspecified site of unspecified female breast
Also known as:
- Dehydration
- Fluid and Electrolyte Balance
- Lack of Fluids
- Fluid Loss
- Body Water Depletion
ICD-10 Codes:
- E860: Dehydration
Also known as:
- Bone, Soft Tissue, or Skin Growth of Unknown Type
- Bone Disease
- Skin Condition
- Bone tumor of unknown nature
- Skin lesion of unknown type
- Soft tissue mass of unknown behavior
ICD-10 Codes:
- D492: Neoplasm of unspecified behavior of bone, soft tissue, and skin
Which procedures does Dr. Ganjoo perform as a Medical Oncologist?
As a Medical Oncologist, procedures performed by a Dr. Kristen Ganjoo may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Ganjoo's office.
Does Dr. Ganjoo accept my insurance?
Dr. Ganjoo accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Ganjoo accept in Stanford, CA?
Dr. Ganjoo in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Central California Alliance for Health
CVS Health (formerly Aetna)
Express Scripts
Medicaid
Medicare
Santa Clara Family Health Plan
State of California
UnitedHealthcare
View All Insurances
Where is Dr. Ganjoo's office located?
Recognitions
Publications
Gastrointestil stromal tumors, version 2.2014.
Jourl of the tiol Comprehensive Cancer Network, 2014
Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2014
A multicenter phase II study of pazopanib in patients with advanced gastrointestil stromal tumors
Anls of oncology, 2014
R1507, a Monoclol Antibody to the Insulin-Like Growth Factor 1 Receptor
JOURL OF CLINICAL ONCOLOGY, 2011
Current and Emerging Pharmacological Treatments for Gastrointestil Stromal Tumour
DRUGS, 2011
A Phase I Study of the Safety
ONCOLOGY, 2011
Soft Tissue Sarcoma
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2010
NCCN Task Force Report: Update on the Magement of Patients with Gastrointestil Stromal Tumors
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2010
Acute myeloid leukemia in patients with gastrointestil stromal tumors treated with Gleevec
LEUKEMIA & LYMPHOMA, 2009
Bevacizumab and cyclosphosphamide, doxorubicin
Leukemia & lymphoma, 2014
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
Cardiac toxicity associated with bevacizumab
LEUKEMIA & LYMPHOMA, 2012
Maintence Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
CANCER INVESTIGATION, 2012
Results of a Phase 1 Study of AME-133v (LY2469298)
CLINICAL CANCER RESEARCH, 2012
The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study
AMERICAN JOURL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
JOURL OF THORACIC ONCOLOGY, 2010
I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (Zevali (R)) Therapy of Low-Grade Refractory
MOLECULAR IMAGING AND BIOLOGY, 2010
Coordite Expression of Colony-Stimulating Factor-1
AMERICAN JOURL OF PATHOLOGY, 2009
The importance of angiogenesis markers
JOURL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008
A phase II study of single agent gemcitabine
AMERICAN JOURL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005
Unusual locations of involvement by maligncies - Case 1. Testicular plasmacytoma
JOURL OF CLINICAL ONCOLOGY, 2003
Germ cell tumor associated primitive neuroectodermal tumors
JOURL OF UROLOGY, 2001
Results of modern therapy for patients with mediastil nonseminomatous germ cell tumors
Ganjoo, K. N., Rieger, K. M., Kesler, K. A., Sharma, M., Heilman, D. K, 2000
Primary mediastil nonseminomatous germ cell tumors
Kesler, K. A., Rieger, K. M., Ganjoo, K. N., Sharma, M., Fineberg, N. , 1999
Lung cancer presenting with solitary bone metastases - Case 1
JOURL OF CLINICAL ONCOLOGY, 1999
Gastrointestinal stromal tumors, version 2.2014.
Journal of the National Comprehensive Cancer Network, 2014
Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014
A multicenter phase II study of pazopanib
Annals of oncology, 2014
R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor
JOURNAL OF CLINICAL ONCOLOGY, 2011
Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour
DRUGS, 2011
A Phase I Study of the Safety
ONCOLOGY, 2011
New Developments in Targeted Therapy for Soft Tissue Sarcoma
CURRENT ONCOLOGY REPORTS, 2010
Soft Tissue Sarcoma
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010
Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas
CANCER, 2010
Trabectedin: an anticancer drug from the sea
EXPERT OPINION ON PHARMACOTHERAPY, 2009
Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec
LEUKEMIA & LYMPHOMA, 2009
Bevacizumab and cyclosphosphamide, doxorubicin
Leukemia & lymphoma, 2014
The Treatment Outcome for Adult Patients with Ewing's Sarcoma.
Current oncology reports, 2013
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
Cardiac toxicity associated with bevacizumab
LEUKEMIA & LYMPHOMA, 2012
Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced
CANCER INVESTIGATION, 2012
Results of a Phase 1 Study of AME-133v (LY2469298)
CLINICAL CANCER RESEARCH, 2012
The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011
A Phase II First-Line Study of Gemcitabine, Carboplatin
JOURNAL OF THORACIC ONCOLOGY, 2010
I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory
MOLECULAR IMAGING AND BIOLOGY, 2010
Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory
CANCER, 2010
A phase II first line study of gemcitabine
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A, 2009
Coordinate Expression of Colony-Stimulating Factor-1
AMERICAN JOURNAL OF PATHOLOGY, 2009
A phase II first-line study of gemcitabine, carboplatin
Krupitskaya, Y., Ganjoo, K., Lavori, P. W., Kumar, A., Clement-Duchene
Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor.
Case reports in oncology, 2009
Breast angiosarcomas: Case series and expression of vascular endothelial growth factor
Case Reports in Oncology, 2009
Opportunistic enteroviral meningoencephalitis
LEUKEMIA & LYMPHOMA, 2009
The importance of angiogenesis markers
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008
Review of erlotinib in the treatement of advanced non-small cell lung cancer
Biologics; Targets & Therapy
Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Biologics : targets & therapy, 2007
Non-Hodgkin lymphoma of the breast
CANCER, 2007
Antiangiogenesis: A new approach to the treatment of lymphoma
LEUKEMIA & LYMPHOMA, 2007
Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety
LEUKEMIA & LYMPHOMA, 2006
Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein
CANCER, 2006
A phase II study of single agent gemcitabine
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005
Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma
JOURNAL OF CLINICAL ONCOLOGY, 2003
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer
ONCOLOGY, 2003
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer
ONCOLOGY, 2002
Germ cell tumor associated primitive neuroectodermal tumors
JOURNAL OF UROLOGY, 2001
Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors
Ganjoo, K. N., Rieger, K. M., Kesler, K. A., Sharma, M., Heilman, D. K, 2000
Positron emission tomography scans in the evaluation of postchemotherapy residual m
Ganjoo, K. N., Chan, R. J., Sharma, M., Einhorn, L. H., 1999
Primary mediastinal nonseminomatous germ cell tumors
Kesler, K. A., Rieger, K. M., Ganjoo, K. N., Sharma, M., Fineberg, N. , 1999
Lung cancer presenting with solitary bone metastases - Case 1
JOURNAL OF CLINICAL ONCOLOGY, 1999
What is Dr. Ganjoo's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Ganjoo's National Provider Identifier (NPI) number is 1669563391.
What common questions do patients ask about Dr. Ganjoo?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Ganjoo
What is Dr. Kristen Ganjoo's specialty?
Dr. Ganjoo is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Ganjoo to book an appointment today.
Is this Dr. Kristen Ganjoo affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Ganjoo is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Medical Oncologist?
Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Kristen Ganjoo accepting new patients in Stanford, CA?
Yes, Dr. Kristen Ganjoo is accepting new patients at this time.
Does Dr. Kristen Ganjoo offer online booking?
Please contact Dr. Ganjoo's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Kristen Ganjoo?
Please contact Dr. Ganjoo's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Kristen Ganjoo have?
Dr. Kristen Ganjoo is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients